The GOG Foundation
Highly Engaged Employees
Non-Profit & Charitable Organizations · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1600 John F Kennedy Blvd Ste 1020, Phila...Phone Number
(215) 854-0770Website
www.gog.orgRevenue
$27.9 MillionIndustry
About The GOG Foundation
The GOG Foundation Org Chart
Is The GOG Foundation your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once The GOG Foundation has new funding data
Check if The GOG Foundation has recently received funding, and reach out quickly before it becomes old news!
The GOG Foundation, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at The GOG Foundation
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on The GOG Foundation recently announced quarterly report
Check out if The GOG Foundation is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if The GOG Foundation had a recent Job posting/layoffs
Product Launch: Get notified when The GOG Foundation launches new products
Recommended Actions
Reach out to Masked Content who joined The GOG Foundation as Masked Content
Find 3 more new buyers
Compare Similar Companies to The GOG Foundation
Compare insights from companies similar to The GOG Foundation, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
The GOG Foundation is experiencing very low activity levels compared to other companies in the Organizations sector.
What does this means?
The GOG Foundation is drawing exceptional interest within the Organizations industry, suggesting notable developments or strong market momentum, learn more about The GOG Foundation.
The GOG Foundation Tech Stack
A closer look at the technologies used by The GOG Foundation
Most Recent Scoops
The GOG Foundation News & Media
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer
OSLO, Norway, April 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced the initiation of the Phase 2 clinical trial VB-C-04. The trial evaluates VB10.16, the company’s off-the-shelf therapeutic cancer vaccine candidate for HPV16-positive cancers, alone or in combination with Roche’s checkpoint inhibitor atezolizumab (Tecentriq®1) in patients with HPV16-poVerastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that it has initiated its international confirmatory Phase 3 RAMP 301 trial (GOG-3097; ENGOT-ov81/NCRI), evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal therapy for the treatment of recurrent low-grade serous ovarian cancer (LGSOC). “Patients and treating physiciansNovocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure today announced that the phase 3 INNOVATE-3 clinical trial in platinum-resistant ovarian cancer did not meet its primary endpoint.Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that it has finalized with the U.S. Food and Drug Administration (FDA) the design of its confirmatory Phase 3 trial to evaluate the combination of avutometinib and defactinib for the treatment of recurrent low-grade serous ovarian cancer (LGSOC). RAMP 301, a randomized global confirmatory trial, will evaluate the ef
Top Non-Profit & Charitable Organizations Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding The GOG Foundation
The GOG Foundation, Inc. (GOG) is a not-for-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies. The GOG is committed to maintaining the highest standards in clinical trials development, execution, analysis and distribution of re... Read More